Freenome (NASDAQ:FRNM) Raised to Strong-Buy at BTIG Research

Freenome (NASDAQ:FRNM) was upgraded by investment analysts at BTIG Research to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

FRNM has been the subject of a number of other reports. Jefferies Financial Group initiated coverage on shares of Freenome in a research report on Monday. They issued a “buy” rating and a $17.00 price target for the company. Leerink Partners assumed coverage on shares of Freenome in a report on Friday. They set an “outperform” rating and a $18.00 price target on the stock. Finally, TD Cowen began coverage on Freenome in a research note on Tuesday. They issued a “buy” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Strong Buy” and a consensus price target of $17.33.

Freenome Stock Up 12.5%

Shares of NASDAQ FRNM opened at $13.00 on Monday. Freenome has a 1-year low of $9.97 and a 1-year high of $14.26.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.